However, serum levels of FasL increase in colon cancer and have a decreased or mutated expression of FasR, TRAIL-R1, and TRAIL-R2 death receptors on their cell surface, promoting survival [53]. The gene discussed is FASLG; the disease is malignant colon neoplasm.